Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Pediatric Research|April 22, 2022
Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic wavesOlivia V Swann, Louisa Pollock, Karl A Holden, et al.
Nature Genetics|March 22, 2006
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitisColin N A Palmer, Alan D Irvine, Ana Terron-Kwiatkowski, et al.
Human Molecular Genetics|August 14, 2003
An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndromeW H Irwin McLean, Alan D Irvine, Kevin J Hamill, et al.
Nature Genetics|April 10, 2007
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczemaAileen Sandilands, Ana Terron-Kwiatkowski, Peter R Hull, et al.
Nature Genetics|October 16, 2012
Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratodermaElizabeth Pohler, Ons Mamai, Jennifer Hirst, et al.
Nature Genetics|January 6, 2009
Loss-of-function mutations of an inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary hypotrichosisYaran Wen, Yang Liu, Yiming Xu, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
JAMA Pediatrics|August 21, 2023
International Pediatric COVID-19 Severity Over the Course of the PandemicYanshan Zhu, Flávia Jacqueline Almeida, J Kenneth Baillie, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Pageof 24